EXECUTIVE SUMMARY

• Spineart Obtains Landmark FDA Approval for BAGUERA® C Cervical Disc Across 1 and 2 Levels: Spineart received FDA approval for its BAGUERA® C cervical disc replacement system supported by two US RCTs (600 patients) and a 10-year follow-up study demonstrating an 85% long-term motion preservation rate.
• Eminent Spine Releases Clinical Outcomes for 3D Printed Titanium Pedicle Screw System: Eminent Spine published clinical study results validating the safety and mechanical stability of the world's first FDA 510(k)-approved 3D printed titanium pedicle screw, reporting zero hardware loosening or revisions.
• Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer: Following 56% Q2 revenue growth ($17.2M), Shoulder Innovations named Jon Osborne CCO to drive global commercial expansion for its InSet™ Shoulder System.

DAILY ANNOUNCEMENTS BY CATEGORY

Joint Reconstruction & Extremities

Shoulder Innovations — Appoints Jon Osborne as Chief Commercial Officer Following Strong Q2 Growth

• Summary: Shoulder Innovations announced the promotion of Jon Osborne to Chief Commercial Officer. Osborne, who previously served as VP of Commercial Development, will lead global commercial organization, sales execution, and surgeon education for the company's InSet™ Shoulder System platform. The appointment follows Q2 2026 financial results where net revenue grew 56% to $17.2M and total implant system sales increased 50% year-over-year.
• Key Details:
• Device/System Name: InSet™ Shoulder System
• Status: Commercial Leadership Appointment / Q2 Financial Milestone
• Clinical Significance: Accelerates surgeon training and market access for inlay glenoid fixation technology designed to mitigate glenoid component loosening in total shoulder arthroplasty.
• Original Source: Shoulder Innovations Press Release — Orthopedics This Week

Spine & Orthobiologics

Spineart — FDA Approval Granted for BAGUERA® C Cervical Disc System for 1 and 2 Levels

• Summary: Spineart announced FDA approval for its BAGUERA® C cervical disc system for both 1-level and 2-level contiguous cervical disc disease indications. The approval is supported by two prospective US randomized controlled trials enrolling nearly 600 patients, alongside 10-year follow-up data published in the European Spine Journal demonstrating an 85% motion preservation rate. The device features a multi-articulating nucleus and titanium-coated PEAK surfaces designed to maintain segmental kinematics.
• Key Details:
• Device/System Name: BAGUERA® C Cervical Disc
• Status: FDA PMA Approved (1 and 2 Contiguous Levels)
• Clinical Significance: Restores cervical motion and reduces adjacent-level degeneration risks, offering a long-term motion-preserving alternative to ACDF.
• Original Source: Spineart Official FDA Clearance Release — Orthopedics This Week

Eminent Spine — Releases Clinical Evidence Validating 3D Printed Titanium Pedicle Screws

• Summary: Eminent Spine published clinical study findings evaluating the long-term performance of its FDA 510(k)-cleared 3D printed titanium pedicle screw platform. The study evaluated patients undergoing posterior lumbar fusion, reporting zero hardware failures, zero revisions, and zero instances of pedicle screw loosening. The porous titanium matrix promoted early osteoconductive fixation and structural stability across complex fusion cases.
• Key Details:
• Device/System Name: 3D Printed Titanium Pedicle Screw System
• Status: Clinical Evidence Released / FDA 510(k) Cleared
• Clinical Significance: Demonstrates superior mechanical anchoring and reduced pseudarthrosis rates in osteopenic and reconstructive spinal surgery.
• Original Source: Eminent Spine Clinical Evidence Release — OrthoSpineNews

Corporate, M&A & Industry Metrics

Cardiff Lexington — Reports Q2 2026 Financial Results Across Orthopaedic Division

• Summary: Cardiff Lexington published its Q2 2026 financial and operational report detailing net revenue performance across its healthcare and orthopaedic surgery subsidiaries. The report outlines operational adjustments as orthopaedic surgical groups navigate changing payer reimbursement structures and expanding outpatient surgical migration.
• Key Details:
• Device/System Name: Orthopaedic Practice Management & ASC Platform
• Status: Q2 2026 Financial Report
• Clinical Significance: Reflects broader healthcare delivery shifts toward ambulatory surgery center (ASC) ownership models and cost-effective outpatient surgical management.
• Original Source: Cardiff Lexington Financial Update — Becker's Spine Review

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)